Who is building the bioprinting economy? Public companies, private innovators and the decentralized science (DeSci) projects funding research on-chain.
Companies & stocks to watch
| Company | Ticker | Why it matters | |
|---|---|---|---|
| 3D Systems | NYSE: DDD | Industrial 3D printing plus regenerative medicine work (Systemic Bio, lung scaffold collaboration). | Live quote ↗ |
| BICO Group (Cellink) | STO: BICO | Bioprinters, bioinks and lab automation; parent of Cellink. | Live quote ↗ |
| CollPlant Biotechnologies | NASDAQ: CLGN | Plant-derived recombinant human collagen (rhCollagen) bioinks. | Live quote ↗ |
| United Therapeutics | NASDAQ: UTHR | Organ manufacturing ambitions: xenotransplant and printed lung scaffolds. | Live quote ↗ |
| Organovo | NASDAQ: ONVO | Early bioprinting pioneer; check recent filings for its current focus. | Live quote ↗ |
| Stratasys | NASDAQ: SSYS | Polymer 3D printing leader with medical and dental lines. | Live quote ↗ |
| Materialise | NASDAQ: MTLS | Medical 3D printing software and patient-specific planning. | Live quote ↗ |
| Aspect Biosystems | Private | Microfluidic bioprinting of therapeutic tissues. | |
| FluidForm Bio | Private | Commercializing FRESH bioprinting from Carnegie Mellon. |
Not financial advice. Tickers and business focus change; always check current filings.
DeSci & biotech tokens
Community-governed funding for longevity research.
Research ↗BIOBIO ProtocolNetwork of “BioDAOs” funding decentralized science.
Research ↗IP-NFTsMoleculeTokenized research IP and funding marketplace.
Research ↗RSCResearchHubOpen science publishing with token incentives.
Research ↗Crypto assets are highly volatile and speculative. Nothing here is investment advice. Do your own research.
Market Stories
Bioprinting Stocks and Companies to Watch
Pure-play bioprinting stocks are rare. Here is a map of the public and private companies shaping the industry.
DeSci Tokens and the Blockchain Funding of Longevity Research
Decentralized science (DeSci) communities pool crypto to fund early research. Here is how it works, and the risks to understand.
Organ-on-a-Chip and Printed Tissue Models Are Changing Drug Testing
The first big business for bioprinting isn’t transplants. It’s testing drugs on human tissue before they ever reach a patient.
Get the weekly market brief
Breakthroughs, tools and weird-but-true science in your inbox. Free, no spam, unsubscribe anytime.